Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias

Loading...
Thumbnail Image

Identifiers

Publication date

Authors

Luaces Rey, Ramón
Medina Villaamil, Vanessa
Álvarez García, Augusto
Valladares-Ayerbes, Manuel

Advisors

Other responsabilities

Journal Title

Bibliographic citation

Prado SM, Cedrún JL, Rey RL, Villaamil VM, García AA, Ayerbes MV, Aparicio LA. Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias. Exp Mol Pathol. 2010 Oct;89(2):197-203.

Type of academic work

Academic degree

Abstract

[Abstract] Objective. Identify candidate SEBs (surrogate endpoint biomarkers) for premalignant trends in head and neck mucosa. Study design. Study, by qPCR (quantitative real-time polymerase chain reaction), the expression of COX-2, EGFR and p53 in 24 biopsies of non-dysplastic oral leukoplakia and contra-lateral normal-appearing mucosa. Results. COX-2 was up-regulated in leukoplakia (79.2%); whereas EGFR and p53 were up-regulated (p > 0.05) in oral contra-lateral normal-appearing mucosa (60% and 46% respectively). Also, p53 expression was correlated with tobacco smoke habits and Spearman's rank correlation coefficient showed a positive linear correlation between p53 and EGFR mRNA expression levels. Conclusions. COX-2 would serve as SEB of oral leukoplakia. The results suggest that p53 appears to be one of the molecular targets of tobacco-related carcinogens in leukoplakia and that the co-expression of p53 and EGFR may play a role in this kind of oral pre-cancerous lesion. More detailed studies of EGFR and p53 should be continued in the future.

Description

Rights

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International Licence (CC-BY-NC-ND 4.0)
Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International Licence (CC-BY-NC-ND 4.0)

Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International Licence (CC-BY-NC-ND 4.0)